Source: Emily Kopp, ROLL CALL, 4/25/19


Congress has made curtailing high drug prices a priority this year and has hauled in some of Big Pharma’s top executives to prove it. Committee hearings on drug prices — the House and Senate have held a half dozen this year — have sought accountability from the industry for drug prices that have forced patients into agonizing decisions about how to budget their lives and caused one-in-four diabetics to ration insulin. A recent study shows the cost of brand-name medicines has increased sharply in the last decade, driven largely by price increases on existing drugs, not new breakthroughs.

For more of this story, click here.